Trajectories of Controller Therapy Use Before and After Asthma-Related Hospitalization in Children and Adults: Population-Based Retrospective Cohort Study.
asthma
clustering
hospitalization
inhaled corticosteroids
quality of care
trajectories
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
26 09 2023
26 09 2023
Historique:
received:
19
06
2023
accepted:
24
08
2023
revised:
19
07
2023
medline:
27
9
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
epublish
Résumé
Inappropriate use of inhaled corticosteroids (ICSs) for asthma impairs control and may cause exacerbation, including asthma-related hospitalization (ARH). In prospective studies, ICS use peaked around ARH, but information on routine care use is limited. Since ARH is a major outcome, controller therapy use in routine care before and after ARH should be documented. This study aimed to distinguish ICS use typologies (trajectories) before and after ARH, and assess their relationships with sociodemographic, disease, and health care characteristics. A retrospective cohort study was performed using a 1% random sample of the French claims database. All patients hospitalized for asthma between January 01, 2013, and December 31, 2015, were classified as either children (aged 1-10 years) or teens/adults (aged ≥11 years). Health care resource use was assessed between 24 and 12 months before ARH. ICS use was computed with the Continuous Measures of Medication Acquisition-7 (CMA7) for the 4 quarters before and after ARH. Initially, the overall impact of hospitalization on the CMA7 value was studied using a segmented regression analysis in both children and teens/adults. Then, group-based trajectory modeling differentiated the groups with similar ICS use. We tested different models having 2 to 5 distinct trajectory groups before selecting the most appropriate trajectory form. We finally selected the model with the lowest Bayesian Information Criterion, the highest proportion of patients in each group, and the maximum estimated probability of assignment to a specific group. Overall, 863 patients were included in the final study cohort, of which 447 (51.8%) were children and 416 (48.2%) were teens/adults. In children, the average CMA7 value was 12.6% at the start of the observation period, and there was no significant quarter-to-quarter change in the value (P=.14) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 34.9% (P=.001), before a significant decrease (P=.01) of 7.0% per quarter. In teens/adults, the average CMA7 value was 31.0% at the start, and there was no significant quarter-to-quarter change in the value (P=.08) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 26.9% (P=.002), before a significant decrease (P=.01) of 7.0% per quarter. We identified 3 and 5 trajectories before ARH in children and adults, respectively, and 5 after ARH for both groups. Trajectories were related to sociodemographic characteristics (particularly, markers of social deprivation) and to potentially inappropriate health care, such as medical management and choice of therapy. Although ARH had an overall positive impact on ICS use trajectories, the effect was often transient, and patient behaviors were heterogeneous. Along with overall trends, distinct trajectories were identified, which were related to specific patients and health care characteristics. Our data reinforce the evidence that inappropriate use of ICS paves the way for ARH.
Sections du résumé
BACKGROUND
Inappropriate use of inhaled corticosteroids (ICSs) for asthma impairs control and may cause exacerbation, including asthma-related hospitalization (ARH). In prospective studies, ICS use peaked around ARH, but information on routine care use is limited. Since ARH is a major outcome, controller therapy use in routine care before and after ARH should be documented.
OBJECTIVE
This study aimed to distinguish ICS use typologies (trajectories) before and after ARH, and assess their relationships with sociodemographic, disease, and health care characteristics.
METHODS
A retrospective cohort study was performed using a 1% random sample of the French claims database. All patients hospitalized for asthma between January 01, 2013, and December 31, 2015, were classified as either children (aged 1-10 years) or teens/adults (aged ≥11 years). Health care resource use was assessed between 24 and 12 months before ARH. ICS use was computed with the Continuous Measures of Medication Acquisition-7 (CMA7) for the 4 quarters before and after ARH. Initially, the overall impact of hospitalization on the CMA7 value was studied using a segmented regression analysis in both children and teens/adults. Then, group-based trajectory modeling differentiated the groups with similar ICS use. We tested different models having 2 to 5 distinct trajectory groups before selecting the most appropriate trajectory form. We finally selected the model with the lowest Bayesian Information Criterion, the highest proportion of patients in each group, and the maximum estimated probability of assignment to a specific group.
RESULTS
Overall, 863 patients were included in the final study cohort, of which 447 (51.8%) were children and 416 (48.2%) were teens/adults. In children, the average CMA7 value was 12.6% at the start of the observation period, and there was no significant quarter-to-quarter change in the value (P=.14) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 34.9% (P=.001), before a significant decrease (P=.01) of 7.0% per quarter. In teens/adults, the average CMA7 value was 31.0% at the start, and there was no significant quarter-to-quarter change in the value (P=.08) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 26.9% (P=.002), before a significant decrease (P=.01) of 7.0% per quarter. We identified 3 and 5 trajectories before ARH in children and adults, respectively, and 5 after ARH for both groups. Trajectories were related to sociodemographic characteristics (particularly, markers of social deprivation) and to potentially inappropriate health care, such as medical management and choice of therapy.
CONCLUSIONS
Although ARH had an overall positive impact on ICS use trajectories, the effect was often transient, and patient behaviors were heterogeneous. Along with overall trends, distinct trajectories were identified, which were related to specific patients and health care characteristics. Our data reinforce the evidence that inappropriate use of ICS paves the way for ARH.
Identifiants
pubmed: 37751244
pii: v9i1e50085
doi: 10.2196/50085
pmc: PMC10565628
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e50085Informations de copyright
©Manon Belhassen, Maeva Nolin, Flore Jacoud, Claire Marant Micallef, Eric Van Ganse. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 26.09.2023.
Références
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Cochrane Database Syst Rev. 2002;(2):CD001005
pubmed: 12076400
Eur Respir J. 2006 Jan;27(1):42-50
pubmed: 16387934
Eur Respir J. 2014 May;43(5):1378-86
pubmed: 24789951
Am J Respir Crit Care Med. 2004 Dec 15;170(12):1281-5
pubmed: 15374842
J Asthma. 2011 Aug;48(6):565-71
pubmed: 21595608
BMC Fam Pract. 2015 Apr 14;16:49
pubmed: 25880641
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1858-1867
pubmed: 30836232
J Asthma. 2019 Jan;56(1):95-103
pubmed: 29437489
Thorax. 2010 Aug;65(8):747-52
pubmed: 20581409
J Allergy Clin Immunol. 2009 Nov;124(5):961-6
pubmed: 19748660
Cochrane Database Syst Rev. 2003;(1):CD001117
pubmed: 12535399
Thorax. 2023 Sep;78(9):860-867
pubmed: 36575040
Biomed Res Int. 2015;2015:217047
pubmed: 26539470
Chest. 2005 Oct;128(4):1968-73
pubmed: 16236843
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
BMC Health Serv Res. 2012 Jun 12;12:155
pubmed: 22691240
Expert Rev Clin Immunol. 2018 Dec;14(12):1055-1063
pubmed: 30286679
J Clin Pharm Ther. 2002 Aug;27(4):299-309
pubmed: 12174032
Ann Fam Med. 2022 Mar-Apr;20(2):116-122
pubmed: 35346926
Eur Respir J. 2002 Aug;20(2):260-7
pubmed: 12212953
Medicine (Baltimore). 2016 Apr;95(15):e3404
pubmed: 27082618
Cochrane Database Syst Rev. 2017 Apr 18;4:CD012226
pubmed: 28417456
J Allergy Clin Immunol. 2011 Dec;128(6):1185-1191.e2
pubmed: 22019090
Curr Med Res Opin. 2018 Dec;34(12):2075-2088
pubmed: 30047292
NPJ Prim Care Respir Med. 2016 Oct 13;26:16076
pubmed: 27735927
Chest. 2014 Apr;145(4):787-793
pubmed: 24337140
Thorax. 2002 Oct;57(10):880-4
pubmed: 12324675
Eur Respir J. 2015 Apr;45(4):994-1018
pubmed: 25504997
Ann Allergy Asthma Immunol. 2020 Mar;124(3):254-260
pubmed: 31862434
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):877-83
pubmed: 27452886
J Asthma. 2022 Sep;59(9):1899-1907
pubmed: 34425724